Affordable Access

deepdyve-link
Publisher Website

HAROW: the first comprehensive prospective observational study comparing treatment options in localized prostate cancer.

Authors
  • Weissbach, Lothar1
  • Stuerzebecher, Steffen2
  • Mumperow, Eberhard3
  • Klotz, Theodor4
  • Schnell, Dietrich2
  • 1 Foundation Men's Health (Stiftung Männergesundheit), Claire-Waldoff-Str. 3, 10117, Berlin, Germany. [email protected]
  • 2 Foundation Men's Health (Stiftung Männergesundheit), Claire-Waldoff-Str. 3, 10117, Berlin, Germany.
  • 3 Urological Practice, Langenfeld, Germany.
  • 4 Department of Urology, Hospital Weiden, Weiden, Germany.
Type
Published Article
Journal
World journal of urology
Publication Date
May 2016
Volume
34
Issue
5
Pages
641–647
Identifiers
DOI: 10.1007/s00345-015-1675-4
PMID: 26373955
Source
Medline
Keywords
License
Unknown

Abstract

Whereas RP remains the main treatment option of localized PCa, active surveillance appears to become an accepted and selectively employed treatment option. Careful selection of patients is documented by the highest proportion of patients with low risk (82.5 %), PSA density <0.2 ng/ml/ml (77.5 %), T1 staging (83.6 %), Gleason score ≤6 (92.5 %), ≤2 positive biopsies (79.4 %), and lowest mean PSA (5.8 ng/ml) in the AS group. The relatively high progression rate in the AS group has to be considered in the context of treatment changes; 71/155 patients had a documented change of treatment and 62 of them with a follow-up period of >3 months.

Report this publication

Statistics

Seen <100 times